 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...7778798081828384858687...100101» |
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=109, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Sep 2018 --> Sep 2020
- | Piqray (alpelisib) / Novartis
Trial completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Oct 2, 2018
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Sep 2018 --> Sep 2020 Trial completion date: Sep 2018 --> Sep 2019
- ||| Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate (clinicaltrials.gov) - Oct 2, 2018
P3, N=130, Recruiting, Sponsor: Pfizer
Trial completion date: Sep 2018 --> Sep 2019 Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Oct 2, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Mar 2019 | Trial primary completion date: Dec 2019 --> Mar 2019 Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Jun 2019
- | letrozole / Generic mfg.
Trial primary completion date, Combination therapy: Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) - Oct 1, 2018
P1, N=12, Recruiting, Sponsor: University of Cincinnati
Trial completion date: Sep 2021 --> Mar 2021 | Trial primary completion date: Dec 2019 --> Jun 2019 Trial primary completion date: Apr 2018 --> Apr 2019
- || Ibrance (palbociclib) / Pfizer
New P2 trial: ASPIRE: Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (clinicaltrials.gov) - Sep 30, 2018
P2, N=42, Not yet recruiting, Sponsor: Emory University
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Sep 28, 2018
P2, N=7, Active, not recruiting, Sponsor: Midwestern Regional Medical Center
Trial primary completion date: Apr 2018 --> Apr 2019 Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018
- | Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Metastases: MONARCH plus: A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (clinicaltrials.gov) - Sep 20, 2018
P3, N=450, Active, not recruiting, Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting | N=32 --> 7 | Trial completion date: Jul 2018 --> Dec 2018 | Trial primary completion date: Jul 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- | Navelbine oral (vinorelbine tartrate oral) / Pierre Fabre
Trial completion: Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA) (clinicaltrials.gov) - Sep 20, 2018
P1, N=60, Completed, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Herceptin (trastuzumab) / Roche
Trial completion: PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (clinicaltrials.gov) - Sep 19, 2018
P2, N=151, Completed, Sponsor: SOLTI Breast Cancer Research Group
Recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion date, Trial primary completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Sep 19, 2018
P2, N=160, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Jul 2019 --> Dec 2019
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Real-world evidence, Real-world: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (clinicaltrials.gov) - Sep 19, 2018
P4, N=260, Recruiting, Sponsor: German Breast Group
Trial completion date: Apr 2021 --> Sep 2021 | Trial primary completion date: Jul 2019 --> Dec 2019 Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Mar 2018
- | letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=74, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Not yet recruiting --> Recruiting | Initiation date: Dec 2017 --> Mar 2018 Trial primary completion date: Jun 2017 --> Jan 2018
- | everolimus / Generic mfg.
Enrollment change, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Sep 18, 2018
P3, N=110, Active, not recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Trial primary completion date: Jun 2017 --> Jan 2018 N=253 --> 110
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Trial completion, Trial completion date, Trial primary completion date: PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) - Sep 18, 2018
P2, N=64, Completed, Sponsor: Istituto Oncologico Veneto IRCCS
N=253 --> 110 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Oct 2018 --> Jan 2018
- | zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
New P2 trial, Combination therapy: RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - Sep 18, 2018
P2, N=62, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- |||| Kisqali (ribociclib) / Novartis
New P2 trial: GOG-3026: Ribociclib and Letrozole Treatment in Ovarian Cancer (clinicaltrials.gov) - Sep 17, 2018
P2, N=51, Not yet recruiting, Sponsor: Gynecologic Oncology Group
- | Kisqali (ribociclib) / Novartis
New P2 trial, Combination therapy, Metastases: Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer. (clinicaltrials.gov) - Sep 14, 2018
P2, N=315, Recruiting, Sponsor: Novartis Pharmaceuticals
- | metformin / Generic mfg., letrozole / Generic mfg.
Trial completion: Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer (clinicaltrials.gov) - Sep 10, 2018
P2, N=208, Completed, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Jan 2018 | Trial primary completion date: Oct 2018 --> Jan 2018 Recruiting --> Completed
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
New P3 trial: Laparoscopic Ovarian Drilling Versus Letrozole In Clomiphene Citrate Resistant Polycystic Ovary (clinicaltrials.gov) - Sep 9, 2018
P3, N=90, Recruiting, Sponsor: Ain Shams University
- ||| Kisqali (ribociclib) / Novartis
Enrollment open, Enrollment change, Metastases: NCI-2018-01284: A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma (clinicaltrials.gov) - Sep 5, 2018
P2, N=76, Recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Active, not recruiting --> Recruiting | N=15 --> 76
- | paclitaxel / Generic mfg.
Enrollment change, Trial withdrawal: ARETTA: Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Sep 4, 2018
P2, N=0, Withdrawn, Sponsor: University of Chicago
Active, not recruiting --> Recruiting | N=15 --> 76 N=60 --> 0 | Not yet recruiting --> Withdrawn
- | letrozole / Generic mfg.
Journal: Orbital fat regeneration following hormonal treatment of metastatic breast carcinoma. (Pubmed Central) - Sep 2, 2018
Treatment with an aromatase inhibitor (letrozole) resulted in tumor regression and orbital fat restoration with a corresponding improvement in orbital volume and enophthalmos on clinical exam...This case illustrates the resilience of orbital soft tissues and ability of orbital fat to regenerate in face of breast cancer metastasis. We hypothesize that endocrine monotherapy, and avoidance of radiation therapy, allowed for differentiation of remaining orbital stem cells, and facilitated the fat regenerative process.
- | Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Enrollment open, Tumor mutational burden, Metastases: BioItaLEE: Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant (clinicaltrials.gov) - Aug 31, 2018
P3, N=350, Recruiting, Sponsor: Novartis Pharmaceuticals
We hypothesize that endocrine monotherapy, and avoidance of radiation therapy, allowed for differentiation of remaining orbital stem cells, and facilitated the fat regenerative process. Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
Enrollment closed: Brovale: Fertility Preservation in Breast Cancer Patients (clinicaltrials.gov) - Aug 28, 2018
P4, N=65, Active, not recruiting, Sponsor: Erasme University Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial: To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (clinicaltrials.gov) - Aug 22, 2018
P2, N=144, Not yet recruiting, Sponsor: International Breast Cancer Study Group
- | Trial completion, Combination therapy, Metastases: BOLERO-6: A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (clinicaltrials.gov) - Aug 22, 2018
P2, N=317, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | taselisib (GDC-0032) / Roche
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer (clinicaltrials.gov) - Aug 21, 2018
P1/2, N=724, Active, not recruiting, Sponsor: Genentech, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Jul 2022 | Trial primary completion date: Nov 2022 --> Jul 2022
- | NN1213 / Novo Nordisk
Trial primary completion date: RIOT-A: Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment (clinicaltrials.gov) - Aug 21, 2018
P2/3, N=128, Recruiting, Sponsor: Sven O. Skouby
Recruiting --> Active, not recruiting | Trial completion date: Nov 2022 --> Jul 2022 | Trial primary completion date: Nov 2022 --> Jul 2022 Trial primary completion date: Mar 2018 --> Oct 2018
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Combination therapy, Metastases: Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer (clinicaltrials.gov) - Aug 16, 2018
P2, N=88, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
- | cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial primary completion date, Metastases: SHPD002: Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients (clinicaltrials.gov) - Aug 15, 2018
P2/3, N=250, Recruiting, Sponsor: RenJi Hospital
Trial primary completion date: Mar 2018 --> Oct 2018 Trial primary completion date: Jul 2018 --> Oct 2018
- || Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=306, Active, not recruiting, Sponsor: NSABP Foundation Inc
Trial primary completion date: Jul 2018 --> Oct 2018 Trial completion date: May 2018 --> Mar 2019 | Trial primary completion date: Apr 2018 --> Jul 2018
- |||| Ibrance (palbociclib) / Pfizer
New P2 trial: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Aug 14, 2018
P2, N=76, Not yet recruiting, Sponsor: NSABP Foundation Inc
- | letrozole / Generic mfg.
New P2 trial: Letrozole Pretreatment With Misoprostol fInduction of Abortion In First-Trimester Missed Miscarriage (clinicaltrials.gov) - Aug 13, 2018
P2, N=80, Not yet recruiting, Sponsor: Ain Shams Maternity Hospital
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
New P2 trial, Stroma, Metastases: BFR-ESS: Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (clinicaltrials.gov) - Aug 10, 2018
P2, N=40, Not yet recruiting, Sponsor: Centre Leon Berard
- | letrozole / Generic mfg.
New P3 trial: A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS (clinicaltrials.gov) - Aug 9, 2018
P3, N=1100, Not yet recruiting, Sponsor: Hongxia Ma
- | Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Aug 9, 2018
P2, N=22, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: May 2018 --> Mar 2019 | Trial primary completion date: Apr 2018 --> Jul 2018 Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Aug 9, 2018
P2, N=56, Recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Sep 2018 --> Feb 2019 | Trial primary completion date: Sep 2018 --> Feb 2019 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- | letrozole / Generic mfg.
Enrollment closed, Phase classification, Surgery: Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Aug 7, 2018
P1, N=200, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Active, not recruiting | Phase classification: PN/A --> P1
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=44, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Phase classification: PN/A --> P1 Trial completion date: Dec 2017 --> Dec 2018
- | Kisqali (ribociclib) / Novartis
New P2 trial, Tumor mutational burden: LEEomic: CompLEEment-1 Canadian Correlative Sub-Study (clinicaltrials.gov) - Aug 3, 2018
P2, N=150, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC) (clinicaltrials.gov) - Aug 2, 2018
P2, N=84, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial completion date: Dec 2017 --> Dec 2018 Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: NEOADAPT: NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (clinicaltrials.gov) - Jul 27, 2018
P2, N=32, Recruiting, Sponsor: Midwestern Regional Medical Center
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
- || PF-06804103 / Pfizer
Trial completion date, Trial primary completion date: PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors (clinicaltrials.gov) - Jul 23, 2018
P1, N=95, Recruiting, Sponsor: Pfizer
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Trial completion date: Nov 2020 --> Feb 2021 | Trial primary completion date: Nov 2020 --> Feb 2021
- | everolimus / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: MAIN-A: Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients (clinicaltrials.gov) - Jul 20, 2018
P3, N=253, Active, not recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Trial completion date: Nov 2020 --> Feb 2021 | Trial primary completion date: Nov 2020 --> Feb 2021 Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Feb 2018 --> Dec 2019
- | Herceptin (trastuzumab) / Roche, trastuzumab/pertuzumab (EG13084) / EirGenix, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial completion date, Trial primary completion date: PER-ELISA: Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Breast Cancer Patients Sensitive to Hormonal Therapy (clinicaltrials.gov) - Jul 20, 2018
P2, N=68, Active, not recruiting, Sponsor: Istituto Oncologico Veneto IRCCS
Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Jun 2020 | Trial primary completion date: Feb 2018 --> Dec 2019 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Oct 2017 --> Oct 2018
- | letrozole / Generic mfg., cyclophosphamide / Generic mfg.
Trial completion date, Trial primary completion date: Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients (clinicaltrials.gov) - Jul 19, 2018
P=N/A, N=200, Recruiting, Sponsor: Capital Medical University
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Oct 2017 --> Oct 2018 Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Sep 2019
- | Kisqali (ribociclib) / Novartis
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jul 18, 2018
P3, N=660, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Aug 2017
- | Ibrance (palbociclib) / Pfizer, dinaciclib (PS-095760) / Ligand, Merck (MSD)
Journal: Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. (Pubmed Central) - Jul 18, 2018
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2018 --> Aug 2017 Collectively, these findings suggest that cell cycle deregulation by LMW-E mediates resistance to AIs and a combination of CDK2 inhibitors and AIs may be an effective treatment in patients with HR-positive tumors that express LMW-E.
- | Ibrance (palbociclib) / Pfizer, fulvestrant / Generic mfg.
Clinical, P2 data, Journal, Combination therapy: PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. (Pubmed Central) - Jul 17, 2018
P2/3
The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer.